Uncategorized

Through flux and fluidity, FDA keeps coming back to rare disease

Published

on

Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version